Industry Flash Session

Control Your Infection Control

Applying qRT-PCR Workflows for Research in SARS-CoV-2

Explore Fungitell STAT® - Watch the Demonstration Video

Driving best practice and maximising IPC clinical workflows using innovative clinical surveillance technology during the COVID pandemic

Assay development in pandemic times: Past, Present and Future

Changing the paradigm of molecular diagnostics in HPV molecular screening

MBT sirius one / sirius IVD systems + CLipART

MBT Pathfinder IVD (with feeder option)

Tools to help optimize good vaccine design

Introduction and use of an Artificial Intelligence imaging device (APAS® Independence) to auto-verify urine cultures

Listening to the needs of healthcare professionals: Copan's innovative approach to the pandemic.

Legionnaire's disease: addressing current medical challenges with a rapid and reliable IVD test based on click chemistry

A rapid SARS-CoV-2 salivary test challenging the reference method - clinical results

TrimericS IgG serology assay in heterologous vaccination

Innovative solutions for an accurate diagnosis of infectious diseases, with a focus on the management of listeriosis

Full-automatic Chemiluminescence Immunoassay system offers total solution for invasive fungal disease diagnostic, especially for aspergillosis infection

Confronting the AMR challenge

Prepared for Viruses and More

The role of a multi-faceted approach in the management of COVID-19

Gepotidacin MOA video

TBA

TBA

COVID Antigen POC testing product demo

COVID Antigen POC testing case study with the Austrian Fire Service

The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with €3,750 million in turnover and more than 17,000 employees. With 10 centres for Research & Development, Menarini’s products are present in the most important treatment areas, including infectious diseases. Pharmaceutical production is carried out in the Group's 18 manufacturing plants, which produce over 572 million packets of product a year and distribute them to five continents.

Evidence Spotlight: Pneumococcal Vaccines Use in Pregnant Women with HIV

Identify Bacterial and Fungal Pathogens with Molecular Diagnostic Test direct from Sample

Managing infectious disease outbreaks through rapid pathogen genome sequencing

Universal Optical DNA Rapid Detection System for Pathogens such as COVID-19, Salmonella, etc.

Passion For the Patient with Puritan Medical Products

QuantuMDx launches Q-POC™:  its novel molecular diagnostic point of care testing system

Reduce time from PBC to actionable results by generating a Liquid Colony™

SARS-CoV-2 diagnostics at R-Biopharm

Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients

In vitro activity of cefiderocol and comparator antimicrobials against carbapenem-non-susceptible Gram-negative isolates from Europe

Mechanisms of carbapenem resistance & Introducing Fetcroja®, the world’s first siderophore cephalosporin

Cefiderocol for the treatment of a systemic infection due to carbapenemase-producing multidrug-resistant Klebsiella pneumoniae

Recurrent neurosurgical site infection by XDR P. aeruginosa treated with Cefiderocol

An overview of Fetcroja clinical data

APEKS-NP: A study of Fetcroja in nosocomial pneumonia

Applicability/Validation of the targeted TaqMan SARS-CoV-2 Mutation Panel for identification of SARS-CoV-2 variants of concern or interest

Next generation SARS-CoV-2 molecular tests based on SpeciMax saliva collection devices

How does the gut microbiome influence the severity of COVID-19

Applied Biosystems™ TaqMan™ COVID-19 2.0 Test Menu

Writing the Future of Infectious Disease